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Abstract
Cystic pancreatic tumours are detected with increasing frequency and remain a clinical problem. Because they have varying potential of 
malignancy the management and decision-making process is a hard task. Guidelines concerning pancreatic cystic tumours indicate mana-
gement with mucinous, serous cystic pancreatic neoplasms and solid pseudopapillary tumours, while the management with pancreatic 
cystic neuroendocrine tumours is not included into these standards. This review tries to find out whether cystic pancreatic neuroendocrine 
tumours are different entities from solid tumours of neuroendocrine origin. The management and differential diagnosis of these neoplasms 
with special focus on features on imaging studies allowing preoperative diagnosis are discussed. (Endokrynol Pol 2018; 69 (3): 320–325)
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Streszczenie
Torbielowate guzy trzustki są coraz częściej wykrywane w badaniach obrazowych i stanowią problem kliniczny. Charakteryzują się 
różnym potencjałem transformacji w guzy złośliwe, dlatego też postępowanie z tego typu zmianami jest trudnym zadaniem. Wytyczne 
dotyczące guzów torbielowatych trzustki odnoszą się głównie do torbielowatych nowotworów surowiczych, śluzowych i guza pseudo-
brodawkowatego, podczas gdy postępowanie z torbielowatymi guzami neuroendokrynnymi trzustki nie zostało w nich uwzględnione. 
W prezentowanej pracy autorzy próbują odpowiedzieć na pytanie, czy torbielowate guzy neuroendokrynne trzustki mają odmienną 
biologię niż guzy lite, przedstawiają również postępowanie oraz diagnostykę różnicową tych zmian, ze szczególnym uwzględnieniem 
charakterystyki torbielowatych nowotworów neuroendokrynnych w badaniach radiologicznych i endosonograficznych pozwalających 
na postawienie przedoperacyjnej diagnozy. (Endokrynol Pol 2018; 69 (3): 320–325)
Słowa kluczowe: guzy neuroendokrynne trzustki, torbiele trzustki, EUS
Introduction
The numbers of detected pancreatic cystic neoplasms 
are increasing. Management with these lesions is a chal-
lenge and often a dilemma because they carry varying 
potential of malignancy. Moreover, pancreatic surgery, 
especially pancreatoduodenectomy, is connected with 
a high morbidity (postoperative complications present 
in 50% of patients), and a significant number of deaths 
(about 5%) [1–3].
International guidelines concerning the manage-
ment with cystic pancreatic tumours recommend man-
agement with mucinous and serous cystic neoplasms 
(MCN, SCN), solid pseudopapillary tumours (SPN), and 
are not focusing on pancreatic cystic neuroendocrine 
tumours (CPEN) [4, 5]. CPENs are often misdiagnosed 
on imaging studies, but these lesions are neoplasms 
we should be aware of and take into account during 
differential diagnosis of cystic pancreatic tumours [6]. 
Moreover, making a false diagnosis can have serious 
consequences, especially in CPENs that are more than 
2 cm in size, which is an indication for surgery according 
to the Polish Network of Neuroendocrine Tumours and 
European Neuroendocrine Tumour Society guidelines 
[7, 8]. In this review, we try to answer to the question: Is 
the biological behaviour of pancreatic cystic neuroendo-
crine tumours different from solid ones? We especially 
focus on features of pancreatic cystic neuroendocrine 
tumours on imaging studies allowing for the proper 
preoperative diagnosis.
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Epidemiology of pancreatic cystic 
neoplasms and pancreatic neuroendocrine 
cystic tumours
Neuroendocrine tumours and pancreatic cystic lesions 
are detected with increasing frequency [9]. Pancreatic 
cysts are found in 20% of magnetic resonance imaging 
(MRI) and 1.2–2.6% of computed tomography (CT) scans 
[4, 10–12]. The prevalence increases with age, and in au-
topsy studies they are detected in 24.7% of patients [13]. 
Most pancreatic cysts are either non-neoplastic le-
sions, like pseudocysts, or tumors with low (SCA), 
intermediate (IPMN-BD — branch duct intrapappilary 
mucinous neoplasma or higher potential of malignant 
transformation (MCN — mucinous cystic neoplasma, 
IPMN-MD — main duct intrapappilary mucinous) 
neoplasms, SPN — solid pappilary neoplasms). Pan-
creatic neuroendocrine tumours (PNEN) constitute 
about 5% of all pancreatic neoplasm with increasing 
incidence of 0.32/100,000/year [7, 14]; among these, 
cystic lesions represent from 13 to 17% of all PNENs 
[15–17]. In the study by Bordeianou et. al. CPENs con-
stituted 7–8% of all resected pancreatic cysts, but this 
diagnosis was preoperatively suspected in a minority 
of patients [18–20]. These cystic lesions are probably 
more prevalent because most of the studies focus only 
on CPNENs after surgery; thus, many of the tumours 
probably remain undetected or misdiagnosed. CPENs 
are usually diagnosed in the 5th and 6th decade of live 
with equal sex distribution and in 44% of cases are 
found incidentally [21, 22].
Clinicopathological features and 
comparison between solid and cystic 
neuroendocrine tumours
It is a matter of a debate whether the CPENs represent 
just a variant of solid tumour or a different entity. It is 
suspected that they appear as a result of haemorrhage, 
necrosis, disturbances of the blood supply caused 
by the tumour capsule, intraductal growth, or cystic 
degeneration of solid PNENs [17, 22]. However, there 
are a lot of clinical differences between solid and cystic 
neuroendocrine tumours [16]. In contrast to solid NENs, 
more common location of CPENs is distal pancreas 
rather than pancreatic head [17]. Cystic tumours are also 
larger and more often symptomatic than solid PNENs 
[16, 17]. It is worth mentioning that the presence of the 
cystic component correlates with the tumour size, and 
its extent is associated with better prognosis [18, 23, 24]. 
Moreover, CPNENs are generally less aggressive than 
solid NENs, taking into account not only lymph node 
distant metastases, but also histopathological features 
like perineural and vascular involvement, presence of 
necrosis, mitotic count, and Ki67 proliferation index [6, 
17]. There are discrepancies between the researchers 
concerning the issue of prognosis. In the largest com-
parative studies of Bordeianou et al. and Koh et al. there 
was no significant difference in five-year survival be-
tween solid and cystic neuroendocrine tumours [17, 18]. 
However, in the study of Paiella et al. on 46 resected 
CPNETs, the tumours were well differentiated (G1, G2-less 
likely) and there was no lesion with Ki67 index over 
5% [25]. Another proof of relatively indolent behaviour 
is the retrospective analysis of Cloyd et al., in which 
there were no cases of purely cystic neuroendocrine 
tumours with metastases, recurrence, or death caused 
by the disease in patients after surgery [24]. It should 
also be mentioned that CPNENs are typically less likely 
to produce hormones and they are more commonly 
associated with MEN1 syndrome than their solid coun-
terparts [18, 24]. Von Hippel-Lindau disease should be 
also taken into account when the diagnosis of CPNEN 
is made [26, 27]. The most common type of functional 
tumour in both solid and cystic NENs is insulinoma [22].
Management with pancreatic cystic 
malignancies
The whole clinical picture should be taken into account 
when the diagnosis of cystic pancreatic neoplasm is 
made. It should include: patient’s age, sex, presence of 
symptoms, location of the lesion, pattern on imaging, 
results of biopsy, and the presence of so-called “high risk 
stigmata” or “worrisome features’ [4]. All of the cystic 
neoplastic lesions have some potential of malignancy, 
which is high for mucinous tumours such as mucinous 
cystadenoma and intraductal papillary mucinous neo-
plasms, main duct type (IPMN-MD), intermediate for 
intraductal papillary mucinous neoplasms, brunch duct 
type (IPMN-BD), and low for SCA. The CT and MRI (ac-
cording to the European experts consensus statement) 
remain a basic modality allowing for the assessment 
of the lesion, its resectability, and the presence of me-
tastases, while endoscopic ultrasound (EUS) remains 
part of a ‘multi-modality diagnostic evaluation’ [5]. The 
EUS and EUS-FNA (fine-needle aspiration) should be 
performed when we suspect that it would change our 
management [5, 28]. According to the international 
guidelines it is indicated when, so-called “worrisome 
features” are found, i.e. size > 3 cm, thickened walls, 
presence of mural nodules, dilation of the pancreatic 
duct, lymphadenopathy, fast growth of the lesion, or 
elevation of serum Ca19.9 marker [4]. However, the 
results of EUS and biopsy do not always allow a final 
preoperative diagnosis. Moreover, the limitation of 
the assessment of tumour morphology alone (without 
biopsy) in EUS is its relatively low overall diagnostic 
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accuracy allowing a diagnosis in 50–73% of cases [5]. 
Furthermore, the disadvantage of EUS-FNA is often 
insufficient material obtained for cytopathological and 
biochemical analysis [5, 29]. EUS with biochemical cyst 
fluid analysis allows for differentiation between muci-
nous, serous, and non-neoplastic lesions with specificity 
of 88% and sensitivity of 63% [5, 30]. Therefore, we are 
not always able to make a final diagnosis of cystic pan-
creatic lesions preoperatively. The surgery is indicated, 
according to European guidelines, in MCN, IPMN-MD, 
and SPT, while in SCA a conservative approach is the 
method of choice [5]. In BD-IPMN indications for 
surgery include: dilation of pancreatic duct > 6 mm, 
presence of mural nodule, and or clinical symptoms, 
otherwise follow-up is indicated [5]. It should be noted 
that pancreatic surgery, even in tertiary centres, is as-
sociated with significant death and complication rates, 
which makes the management with cystic tumours 
a dilemma [31].
Pancreatic cystic neuroendocrine tumour 
on radiological imaging and endoscopic 
ultrasound
Pancreatic neuroendocrine tumours are typically solid 
tumours with peripheral enhancement and increased 
vascularisation on ultrasound Doppler imaging and CT 
scan [21]. CPENs should be suspected when cysts with ar-
terial and venous enhancement are found in CT [18, 32]. 
CPENs in CT scan are mostly mixed solid-cystic le-
sions, and according to a study by Kawamoto et al. 
a minority of the lesions (17.8%) are predominantly 
cystic [32]. Calcifications are rare but can be present [21]. 
However, a few analyses showed that there are no 
characteristic features of CPNENs allowing for preop-
erative diagnosis in CT scan [33]; thus, EUS might be 
helpful in establishing a final diagnosis. The study by 
Khasab et al. showed increased diagnostic yield and 
accuracy of EUS over CT and MRI in presurgical pre-
diction of cystic pancreatic lesions [34]. Unfortunately, 
there is no unique appearance of CPENs in EUS, and 
patterns observed in the examination include: cystic or 
mixed solid-cystic lesions, and unilocular or microcystic 
tumour with or without septations [26, 35]. The only 
ultrasound feature that is present more frequently in 
EUS, in comparison to mucinous cysts, is the presence 
of thick wall and well-defined margins of the lesion 
[26, 35]. The superiority of EUS over CT or MRI is the 
possibility to assess small lesions and to perform biopsy 
with cytological and biochemical analysis of fluid [36]. 
In the study by Morales-Oyarvide et al. biopsy allowed 
for a proper presurgical diagnosis in a significant pro-
portion (77%) of patients [19]. Examples of EUS images 
of cystic pancreatic neuroendocrine tumour from our 
Figure 1. Endoscopic ultrasound of microcystic neuroendocrine tumour 
of the pancreatic head in a 43-year-old woman. The tumour mimics 
cystic serous adenoma. The diagnosis of neuroendocrine origin of the 
lesion was made on the pathological assessment of material obtained 
during surgery. Biopsy under EUS guidance was inconclusive
Rycina 1. Endoskopowa ultrasonografia mikrotorbielowatego 
neuroendokrynnego mikrotorbielowatego guza głowy trzustki 
u 43-letniej kobiety. Guz przypomina torbielakogruczolaka 
surowiczego. Ostateczna diagnoza została postawiona na podstawie 
oceny patomorfologicznej materiału pooperacyjnego. Biopsja pod 
kontrolą EUS nie była wystarczająca do postawienia rozpoznania
Figure 2. EUS of a 37-year-old patient with MEN1 syndrome 
shows a cystic pancreatic tail neuroendocrine tumour with 
characteristic thin wall
Rycina 2. Badanie EUS u 37-letniej pacjentki z zespołem MEN1 
— uwidoczniono zmianę w ogonie trzustki z typową dla guzów 
neuroendokrynnych pogrubiałą ścianą
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department are presented in Figure 1 and 2. CT and 
MRI images are presented in Figure 3 and 4.
Differential diagnosis
Despite our knowledge of cystic and neuroendocrine 
tumour biology and guidelines we have at our disposal, 
making a presurgical and final diagnosis of cystic pan-
creatic tumour is not always possible. The limitations 
are the sensitivity and specificity of imaging methods 
and biopsy (see chapters above). CPNENs are often 
misdiagnosed on imaging studies [6]. The differential 
diagnosis of CPNENs includes mainly mucinous tu-
mours (IPMN, MCN), solid pseudopapillary tumour, 
cystic metastases to pancreas, cystadenocarcinoma, and 
atypical (not honeycomb pattern) serous cystadenoma, 
which can be similar to CPNEN not only in CT scan 
but also in scintigraphy [37]. The biggest challenge 
(due to different clinical management) is to properly 
diagnose patients with CPNENs and qualify patients 
with lesions > 2 cm to surgery. The mistake that should 
be avoided is misdiagnosing CPEN with branch duct 
IPMN and then to treat the patient conservatively. 
International guidelines define branch duct IPMN as 
a “pancreatic cysts > 5 mm in diameter that commu-
nicate with the main pancreatic duct”, and typically it 
resembles a bunch of grapes [4, 21]. CPENs, in contrast 
to IPMN-BD, typically do not communicate with the 
pancreatic duct [5, 6]. Furthermore, on imaging studies 
(with use of CT/MRI) only 33% of CPNENs had high-
risk stigmata and 18% had worrisome features, which, 
judging only on these modalities, could convince us 
to treat CPNENs conservatively [19]. EUS has become 
an important diagnostic tool and a valuable part of 
the multimodal approach to pancreatic cystic lesions. 
However, this modality, in terms of diagnosing cystic 
pancreatic tumours, has its limitations. According to 
the study of Morales-Oyarvide et al. the diagnosis of 
CPNEN was suspected in EUS only in 47% of post-opera-
tively confirmed cases [19]. The results of cystic pancreatic 
fluid analysis were also not conclusive. Fluid analysis in 
CPNENs showed low viscosity and low levels of CEA 
(in contrast to mucinous tumours) and amylase [19, 21]. 
 In contrast to serous cystadenoma, CPNENs have 
low or absent glycogen content in fluid aspirate [21]. 
However, currently used markers do not allow a final 
diagnosis to be made, and new markers of CPNENs 
are being sought. In the study of Oruc et al. cystic fluid 
levels of chromogranin A(CgA) (non-specific serum 
marker of neuroendocrine tumours) were not charac-
teristic for CPNENs and did not have any value in the 
differential diagnosis of pancreatic cystic lesions [38]. 
In contrast to the abovementioned methods, EUS-FNA 
with cytological examination of cells is the more spe-
cific method when CPEN is suspected. In the studies 
of Morales-Oyarvide et al. and Singhi et al. cytological 
analysis allowed a proper diagnosis in 77% to 84% of 
cases [19], and in the study of Yoon et al. diagnostic 
positive cytology was more frequent in patients with 
CPNENs than in those with mucinous cysts [19]. Typi-
cally, CPENs are composed of polygonal, plasmacytoid 
looking cells with round or oval and slightly peripheral 
nuclei, nodular, dull, “salt and pepper’ chromatin, and 
positive staining for chromogranin A and synaptophysin 
Figure 3. MRI, T2-weighted image of a 60-year-old man with a cystic 
neuroendocrine tumour of the pancreatic body (NET G1) manifesting 
as hyperintensive lesion. The tumour was found incidentally
Rycina 3. MRI, obraz T2-zależny, przypadkowo znaleziona 
hiperintensywna zmiana torbielowata u 60-letniego mężczyzny 
(NET G1)
Figure 4. Abdominal CT scan of a 31-year-old woman with 
a cystic neuroendocrine tumour of the pancreatic tail
Rycina 4. Tomografia komputerowa u 31-letniej pacjentki 
z neuroendokrynnym guzem torbielowatym ogona trzustki
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[6, 19, 26]. The possibility of obtaining positive cytology 
is significantly higher in patients with CPNENs than in 
those with mucinous cystic neoplasms [26]. Therefore, 
EUS-FNA with cytological analysis and staining for 
neuroendocrine tumour markers should be performed 
whenever CPEN is suspected [36]. Postoperative his-
topathological differential diagnosis should include 
especially solid pseudopapillary tumour and acinar 
cell carcinoma [6, 39]. 
How should we manage pancreatic cystic 
pancreatic neuroendocrine tumours?
As was mentioned, the preoperative and definitive dia-
gnosis of pancreatic cystic tumours is often a hard task, 
and cystic lesions are often incorrectly classified [17]. 
Cystic pancreatic tumour should be suspected when 
a cystic or mixed solid-cystic tumour with peripheral 
enhancement is found in CT scan and/or cystic tumour 
with thick walls is seen in EUS. In such cases EUS with 
FNA should be performed. When the diagnosis of 
neuroendocrine tumour is made we should follow the 
guidelines concerning the solid tumours and follow-up 
the tumours that are no more than 2 cm in size. Patients 
with larger lesions should be referred to a surgeon. 
However, we should take into account and evaluate the 
hormonal activity and remember that neuroendocrine 
tumours with cystic component have less aggressive 
behaviour than solid ones [17]. This fact is of great 
importance in older patients with comorbidities. Fur-
thermore, when surgery is indicated, more conservative 
surgery types (enucleation, spleen preserving distal 
pancreatectomy) should be considered [17].
Summary
We can conclude that cystic PNENs probably represent 
a different entity than solid tumours, which we should 
be aware of in differential diagnosis of pancreatic 
cystic tumours. These tumours have different clinical 
characteristics; therefore, the presence of a cystic com-
ponent should be taken into account in decision making 
processes in patients with pancreatic neuroendocrine 
tumours. The limitations of the presented data are the 
relatively small groups of patients included in the stud-
ies and the fact that analysis focused on patients after 
surgical resections.
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